All In MedTech

Device Trial Radar · NCT06625749

Evaluate the Safety and Effectiveness of the AccuraSee™ IOPCL for Secondary Implantation in the Capsular Bag to Improve Near and/or Intermediate Vision Following Previous Cataract Surgery

Early Feasibility Study to Evaluate the Safety and Effectiveness of the AccuraSee™ IOPCL for Secondary Implantation in the Capsular Bag to Improve Near and/or Intermediate Vision Following Previous Cataract Surgery

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 23, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
OnPoint Vision IncNot on our public-company list
Sponsor type
Industry
First posted
Oct 3, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a study to evaluate the safety and effectiveness of the AccuraSee™ intraocular pseudophakic capsular lens (IOPCL) to improve near and/or intermediate vision following previous cataract surgery.

Conditions

  • Refractive Surgery
  • Refractive Error - Myopia

Interventions

  • Accurasee™ IOPCLDevice

    Intraocular pseudophakic capsular lens (IOPCL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in uncorrected near visual acuity (UCNVA) at 40 cm/16 inchesTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Midwest Vision Partners

    Cleveland, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.